IRA updates and making sense of the chaos in Washington, with Alice Valder Curran

Last year, Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert in Washington, DC joined host Jonah Comstock on the pharmaphorum podcast to talk about the intended and unintended consequences of the drug pricing negotiation provisions in the Inflation Reduction Act.

On today’s episode, Curran joins us once again for an update on the IRA, looking at the second batch of drugs announced in January, recent messaging from the Centers for Medicare and Medicaid Services and what it might communicate about their thinking, and more analysis of IRA’s consequences, including a recent study on the impact of the IRA on early stage investment.

She also talks about the possibility that, because of perverse incentives for pharmacy benefit managers, patient access to medications negotiated under the IRA could actually get worse. And she looks ahead to the third round of negotiations, which will see Part D drugs, including Keytruda, become eligible.

While the IRA was the main focus of discussion, Curran and Comstock discuss a lot more about the current chaotic environment in DC, including the potential impact of layoffs on the functioning of agencies like the CMS and FDA, the outlook for the possibility of IRA reform under the Trump administration, and the recent dispatch from Secretary of Health and Human Services Robert F. Kennedy Jr indicating a change in policy around notice and comment rulemaking. 

Things are happening fast in the United States government and the ripples could have big effects for the pharma industry. Tune in for the low-down from an expert insider.